OTCMKTS:BCTXF BriaCell Therapeutics (BCTXF) Stock Price, News & Analysis $0.76 +0.02 (+3.11%) As of 08/18/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About BriaCell Therapeutics Stock (OTCMKTS:BCTXF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BriaCell Therapeutics alerts:Sign Up Key Stats Today's Range$0.75▼$0.7950-Day Range$0.63▼$3.5352-Week Range$3.25▼$17.50Volume621,836 shsAverage Volume1,859 shsMarket Capitalization$589.04 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada. Read More Receive BCTXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCTXF Stock News HeadlinesBriaCell Announces Share Consolidation to Maintain Nasdaq ComplianceAugust 9, 2025 | theglobeandmail.comBriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast CancerJuly 15, 2025 | finance.yahoo.comNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.August 22 at 2:00 AM | Brownstone Research (Ad)BriaCell Therapeutics Corp.: BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast CancerJuly 8, 2025 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Bria-OTS Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint InhibitorMay 27, 2025 | finanznachrichten.deBriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical MilestoneApril 24, 2025 | msn.comBriaCell confirms 100% resolution of lung metastasis with Bria-OTSApril 24, 2025 | markets.businessinsider.comBriaCell reports survival boost in breast cancer studyApril 18, 2025 | uk.investing.comSee More Headlines BCTXF Stock Analysis - Frequently Asked Questions How have BCTXF shares performed this year? BriaCell Therapeutics' stock was trading at $0.5558 at the beginning of 2025. Since then, BCTXF shares have increased by 37.3% and is now trading at $0.7630. How do I buy shares of BriaCell Therapeutics? Shares of BCTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BCTXF CIKN/A Webwww.briacell.com Phone(604) 921-1810FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.68 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-786.77% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.55) per share Price / Book-0.17Miscellaneous Outstanding Shares772,000Free FloatN/AMarket Cap$589.04 thousand OptionableNot Optionable Beta1.09 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:BCTXF) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access